The clinical approach to small fiber neuropathy and painful channelopathy

Practical Neurology

Volumn 14, Issue 6, 2014, Pages 368-379

  Themistocleous, Andreas C ^a   Ramirez, Juan D ^a   Serra, Jordi ^b,c   Bennett, David L H ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BARCELONA   (Spain)

^c MC Mutual   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHANNELOPATHIES; GENETICS; HUMAN; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES;

CHANNELOPATHIES; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84924798837     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/practneurol-2013-000758     Document Type: Review

References (63)

1. Hoeijmakers JG, Faber CG, Lauria G, et al. Small-fibre neuropathies-advances in diagnosis, pathophysiology and management. Nat Rev Neurol 2012;8:369–79.
2. Hovaguimian A, Gibbons CH. Diagnosis and treatment of pain in small-fiber neuropathy. Curr Pain Headache Rep 2011;15:193–200.
3. Waxman SG. Painful Na-channelopathies: an expanding universe. Trends Mol Med 2013;19:406–9.
4. Kremeyer B, Lopera F, Cox JJ, et al. A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron 2010;66:671–80.
5. Devigili G, Tugnoli V, Penza P, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008;131:1912–25.
6. McGlone F, Reilly D. The cutaneous sensory system. Neurosci Biobehav Rev 2010;34:148–59.
7. Hensel H, Boman KK. Afferent impulses in cutaneous sensory nerves in human subjects. J Neurophysiol 1960;23:564–78.
8. Sheehan D, Pick J. The rami communicantes in the rhesus monkey. J Anat 1943;77:125–39.
9. Cohen S, Levi-Montalcini R, Hamburger V. A nerve growth-stimulating factor isolated from sarcomas 37 and 180. Proc Natl Acad Sci USA 1954;40:1014–18.
10. Rotthier A, Baets J, Timmerman V, et al. Mechanisms of disease in hereditary sensory and autonomic neuropathies. Nat Rev Neurol 2012;8:73–85.
11. Hoitsma E. Small fiber neuropathy: a common and important clinical disorder. J Neurol Sci 2004;227:119–30.
12. Lauria G. Small fibre neuropathies. Curr Opin Neurol 2005;18:591–7.
13. Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012;11:521–34.
14. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst 2004;9:26–53.
15. Brussee V, Cunningham FA, Zochodne DW. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 2004;53:1824–30.
16. Cherry CL, Skolasky RL, Lal L, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 2006;66:867–73.
17. Kamerman PR, Moss PJ, Weber J, et al. Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. J Peripher Nerv Syst 2012;17:19–31.
18. Adams D. Hereditary and acquired amyloid neuropathies. J Neurol 2001;248:647–57.
19. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011;10:1086–97.
20. Faber CG, Hoeijmakers JG, Ahn HS, et al. Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 2012;71:26–39.
21. Dib-Hajj SD, Yang Y, Black JA, et al. The Nav1.7 sodium channel: from molecule to man. Nat Rev Neurosci 2013;14:49–62.
22. Persson AK, Liu S, Faber CG, et al. Neuropathy-associated Nav1.7 variant I228M impairs integrity of dorsal root ganglion neuron axons. Ann Neurol 2013;73:140–5.
23. Faber CG, Lauria G, Merkies IS, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci USA 2012;109:19444–9.
24. Periquet MI, Novak V, Collins MP, et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology 1999;53:1641–7.
25. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285–93.
26. Truini A, Romaniello A, Galeotti F, et al. Laser evoked potentials for assessing sensory neuropathy in human patients. Neurosci Lett 2004;361:25–8.
27. Serra J, Bostock H, Solà R, et al. Microneurographic identification of spontaneous activity in C-nociceptors in neuropathic pain states in humans and rats. Pa in 2011;153:42–55.
28. Chong PS, Cros DP. Technology literature review: quantitative sensory testing. Muscle Nerve 2004;29:734–47.
29. Maier C, Baron R, Tölle TR, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 2010;150:439–50.
30. Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 2006;123:231–43.
31. Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152:14–27.
32. Rolke R, Magerl W, Campbel KA, et al. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain 2006;10:77–88.
33. McCarthy BG, Hsieh ST, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995;45:1848–55.
34. Lauria G, Hsieh ST, Johansson O, et al. European FedeEuropean Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2010;17:903–12.
35. Lauria G, Devigili G. Skin biopsy as a diagnostic tool in peripheral neuropathy. Nat Clin Pr Neurol 2007;3:546–57.
36. Kennedy WR, Nolano M, Wendelschafer-Crabb G, et al. A skin blister method to study epidermal nerves in peripheral nerve disease. Muscle Nerve 1999;22:360–71.
37. Panoutsopoulou IG, Wendelschafer-Crabb G, Hodges JS, et al. Skin blister and skin biopsy to quantify epidermal nerves: a comparative study. Neurology 2009;72:1205–10.
38. Thompson RJ, Doran JF, Jackson P, et al. PGP 9.5-a new marker for vertebrate neurons and neuroendocrine cells. Brain Res 1983;278:224–8.
39. Wang L, Hilliges M, Jernberg T, et al. Protein gene product 9.5-immunoreactive nerve fibres and cells in human skin. Cell Tissue Res 1990;261:25–33.
40. Lauria G, Bakkers M, Schmitz C, et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst 2010;15:202–7.
41. Hossain P, Sachdev A, Malik RA. Early detection of diabetic peripheral neuropathy with corneal confocal microscopy. Lancet 2005;366:1340–3.
42. Ewing DJ, Martyn CN, Young RJ, et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985;8:491–8.
43. Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004;41:171–4.
44. Fertleman CR, Baker MD, Parker KA, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006;52:767–74.
45. Han C, Rush AM, Dib-Hajj SD, et al. Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7. Ann Neurol 2006;59:553–8.
46. Cregg R, Laguda B, Werdehausen R, et al. Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia. Neuromolecular Med 2013;15:265–78.
47. Segerdahl AR, Xie J, Paterson K, et al. Imaging the neural correlates of neuropathic pain and pleasurable relief associated with inherited erythromelalgia in a single subject with quantitative arterial spin labelling. Pain 2012;153:1122–7.
48. Dib-Hajj SD, Rush AM, Cummins TR, et al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005;128:1847–54.
49. Bandell M, Story GM, Hwang SW, et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 2004;41:849–57.
50. Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care 2007;30:2608–12.
51. Souayah N, Chin RL, Brannagan TH, et al. Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol 2008;15:1300–3.
52. Morozumi S, Kawagashira Y, Iijima M, et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren’s syndrome. J Neurol Sci 2009;279:57–61.
53. Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003;28:703–10.
54. Kamerman P, Wadley A, Cherry C. HIV-associated sensory neuropathy: risk factors and genetics. Curr Pain Headache Rep 2012;16:226–36.
55. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002;50:393–413.
56. Smith BH, Lee J, Price C, et al. Neuropathic pain: a pathway for care developed by the British Pain Society. Br J Anaesth 2013;111:73–9.
57. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113–e88.
58. Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374: 1252–61.
59. Phillips TJ, Cherry CL, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS ONE 2010;5:e14433.
60. Clifford DB, Simpson DM, Brown S, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr 2012;59:128–33.
61. Freeman R. Autonomic peripheral neuropathy. Lancet 2005;365:1259–70.
62. Yang Y, Dib-Hajj SD, Zhang J, et al. Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Nav1.7 mutant channel. Nat Commun 2012;3:1186.
63. Hazenberg BP, van Rijswijk MH, Piers DA, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006;119:355.e15–e24.